Shares of Tianxing Medical (01609) rallied more than 7% in the afternoon session, last trading up 7.07% at HK$149.9 with turnover reaching HK$30.02 million. The move comes after the company announced its selection for inclusion in the Hang Seng Composite Index, effective September 7.

Following the index inclusion, the company's shares are expected to meet the criteria for trading under both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. This development is anticipated to enhance the company's market visibility and investment appeal, while broadening its potential investor base.

According to the company's interim report, first-half revenue reached approximately RMB 163 million, representing a 21.6% year-on-year increase. Adjusted net profit climbed 24.3% to around RMB 48.9 million. Notably, overseas sales revenue surged 70.6% from the same period last year to approximately RMB 40.7 million, lifting the overseas revenue share to 24.9% of total revenue.

Additionally, the company announced a share repurchase plan of up to 2.9 million H-shares, representing approximately 5.29% of its total issued H-share capital.